ReShape Lifesciences, Inc.

How big is ReShape Lifesciences, Inc.?

As of Jun 18, ReShape Lifesciences, Inc. has a market capitalization of 6.37 million, with net sales of 7.17 million and a net profit of -3.46 million over the last four quarters. The company reported shareholder's funds of -0.25 million and total assets of 4.83 million as of Dec 24.

Market Cap: As of Jun 18, ReShape Lifesciences, Inc. has a market capitalization of 6.37 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ReShape Lifesciences, Inc. reported net sales of 7.17 million and a net profit of -3.46 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -0.25 million and total assets of 4.83 million.

What does ReShape Lifesciences, Inc. do?

ReShape Lifesciences, Inc. is a medical device company focused on obesity treatment, with recent net sales and profit of $1 million each. It has a market cap of $6.37 million and operates at a loss, reflected in its negative P/E and return on equity metrics.

Overview: <BR>ReShape Lifesciences, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obesity and overweight individuals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6.37 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.03 <BR>Return on Equity: -501.25% <BR>Price to Book: 5.18<BR><BR>Contact Details: <BR>Address: 5421 Avenida Encinas Ste F, CARLSBAD CA: 92008-4410 <BR>Tel: 1 858 4802400 <BR>Fax: 1 302 6365454 <BR>Website: http://www.obalon.com/

Should I buy, sell or hold ReShape Lifesciences, Inc.?

Who are in the management team of ReShape Lifesciences, Inc.?

As of March 2022, the management team of ReShape Lifesciences, Inc. includes Kim Kamdar (Independent Chairman), Andrew Rasdal (CEO), William Plovanic, Raymond Dittamore, Douglas Fisher, and Lesley Howe (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of ReShape Lifesciences, Inc. includes the following individuals:<BR><BR>- Ms. Kim Kamdar, Independent Chairman of the Board<BR>- Mr. Andrew Rasdal, President, Chief Executive Officer, and Director<BR>- Mr. William Plovanic, Director<BR>- Mr. Raymond Dittamore, Independent Director<BR>- Dr. Douglas Fisher, Independent Director<BR>- Mr. Lesley Howe, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is ReShape Lifesciences, Inc. overvalued or undervalued?

As of August 16, 2021, ReShape Lifesciences, Inc. is considered a risky investment due to its negative financial metrics, including a Price to Book Value of 2.51, an EV to EBITDA of -0.09, a Return on Equity of -501.25%, and a year-to-date stock return of -98.52%, significantly underperforming the S&P 500.

As of 16 August 2021, ReShape Lifesciences, Inc. has moved from a grade of "does not qualify" to "risky," indicating a significant deterioration in its valuation outlook. The company is overvalued, given its negative financial metrics, including a Price to Book Value of 2.51 and an EV to EBITDA of -0.09. Additionally, the Return on Equity (ROE) stands at a staggering -501.25%, which further underscores the company's financial struggles.<BR><BR>In comparison to its peers, ReShape Lifesciences exhibits worse performance metrics, with NanoVibronix, Inc. showing a P/E of -0.9426 and EV to EBITDA of -0.2892, while INVO BioScience, Inc. has an EV to EBITDA of -0.6859. The company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -98.52% compared to the S&P 500's 12.22%, reinforcing the notion that ReShape Lifesciences is not a viable investment at this time.

Is ReShape Lifesciences, Inc. technically bullish or bearish?

As of May 27, 2025, ReShape Lifesciences, Inc. is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearishness, despite a mildly bullish MACD on longer time frames, while the stock has underperformed the S&P 500 with a year-to-date return of -98.52%.

As of 27 May 2025, the technical trend for ReShape Lifesciences, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating bearishness and weekly Bollinger Bands also showing a bearish signal. While the MACD is mildly bullish on both weekly and monthly time frames, the overall sentiment is tempered by the Dow Theory and KST both indicating a mildly bearish stance on a weekly basis. The RSI shows no signal on the weekly chart but is bullish on the monthly chart, suggesting some divergence in momentum. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -98.52% versus the S&P 500's 12.22%.